Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
General Internal Medicine
•
NCI-CCC Lymphoma Tumor Board Question
•
City of Hope
How would you approach a patient with lymphoma (i.e. DLBCL) who has developed chylous pleural effusions while on therapy?
Related Questions
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
How would you manage a patient w/ blastoid variant MCL given data w/ all the current BTKi regimens TRIANGLE, BOVEN, and TRAVERSE
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?
After the MAJESTEC-3 results, and once approved, what is your approach to choosing between Tec-Dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
